Beyond Series B: Financial Strategies for Scaling BioTech Companies [Video]

Securing Series B funding is a major win for BioTech companies, but what comes after can be the real challenge. So, what happens next? Well once the check clears, it’s all about scaling up, especially when it comes to managing financials. At this stage, companies are usually gearing up for clinical trials, expanding their teams, and getting everything in order for potential IPOs.

It’s exciting but also tricky—especially if you’re not prepared for the financial challenges that come with growth. Let’s dig into how BioTech companies can effectively manage their financials as they scale post-Series B.

Series B is where things start to get real for BioTech companies. At this point, early research and development have shown enough promise to attract serious investors, and now it’s time to take things to the next level—namely, getting products ready for market. This often means pouring more money into clinical trials and ramping …